BOTTINI, Alberto
 Distribuzione geografica
Continente #
NA - Nord America 755
EU - Europa 360
AS - Asia 187
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 1.305
Nazione #
US - Stati Uniti d'America 753
DE - Germania 150
CN - Cina 105
UA - Ucraina 80
SG - Singapore 42
GB - Regno Unito 35
RU - Federazione Russa 33
HK - Hong Kong 26
FI - Finlandia 14
IT - Italia 14
IE - Irlanda 12
TR - Turchia 11
CZ - Repubblica Ceca 9
FR - Francia 9
CA - Canada 2
CH - Svizzera 2
EU - Europa 2
BR - Brasile 1
GE - Georgia 1
HU - Ungheria 1
IN - India 1
KR - Corea 1
SE - Svezia 1
Totale 1.305
Città #
Fairfield 115
Woodbridge 94
Jacksonville 60
Ann Arbor 53
Houston 52
Seattle 52
Ashburn 49
Dearborn 44
Singapore 38
Cambridge 36
Wilmington 31
Chandler 29
New York 27
Hong Kong 26
Princeton 24
Nanjing 18
Beijing 15
Shanghai 13
Dublin 12
Helsinki 10
Istanbul 10
Brno 9
Nanchang 8
Shenyang 8
Nürnberg 7
Changsha 6
Brescia 5
Kunming 5
San Diego 5
Hebei 4
Des Moines 3
Jinan 3
Tianjin 3
Fuzhou 2
Haikou 2
Hangzhou 2
Hefei 2
Lancaster 2
Lanzhou 2
London 2
Romola 2
San Francisco 2
Toronto 2
Berlin 1
Boardman 1
Changchun 1
Chicago 1
Guangzhou 1
Jiaxing 1
Kilburn 1
Los Angeles 1
Lviv 1
Milan 1
Munich 1
New Bedfont 1
Newark 1
Ningbo 1
Orange 1
Quzhou 1
São Paulo 1
Taizhou 1
Verano Brianza 1
Verona 1
Wuhan 1
Totale 915
Nome #
Neoadjuvant treatment approach: The rosetta stone for breast cancer? 153
Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies. 129
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 123
Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients 117
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. 112
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers 112
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials 111
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials 107
Effect of primary letrozole treatment on tumor expression of mTOR and HIF-1α and relation to clinical response 102
Phosphorylated ERα, HIF-1α, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer 91
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen 86
Corrigendum to "Gene expression profiling in breast cancer: A clinical perspective" [The Breast 22 (2013) 109-120 [doi:10.1016/j.breast.2013.01.016.]] 47
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease 16
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer 13
Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial 11
Totale 1.330
Categoria #
all - tutte 6.256
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.256


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020284 0 0 0 0 24 63 52 43 25 52 7 18
2020/2021169 5 32 2 22 11 19 5 18 14 23 15 3
2021/202296 15 11 6 4 2 3 2 10 7 9 5 22
2022/202390 12 0 3 2 7 23 0 15 15 0 8 5
2023/2024123 7 2 15 1 5 27 6 7 27 0 1 25
2024/202560 1 1 3 36 19 0 0 0 0 0 0 0
Totale 1.330